Thank you
Thank you for participating in today's webinar. We encourage you to complete the activity evaluation if you have not already done so.
Webinar evaluation: https://www.surveymonkey.com/r/XDWHFVP
A recording of this webinar will be available in the Epilepsy Learning Institute in the coming weeks. If you have any questions, please contact AES at education@aesnet.org.
Description
Registration Fees
Target Audience
Epileptologists, neurologists, professionals in epilepsy care, and other interested healthcare professionals
Learning
Objectives
Following participation in this activity, participants should be able to:
- Review and discuss the evidence-based clinical practice guideline on treatment of convulsive status epilepticus in adults and in children;
- Appropriately employ the algorithm on the treatment of convulsive status epilepticus;
- Discuss the need for well-designed research to answer the clinically relevant questions identified in this evidence-based review and guideline development process.
Faculty
Moderator: Dennis J. Dlugos, M.D., Childrens Hospital of Philadelphia, Philadelphia, PA
Chair, AES Education and Professional Development Committee
Presenter: Tracy Glauser, M.D., Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Chair, AES Guidelines Committee
FACULTY, PLANNING COMMITTEE, REVIEWERS’ DISCLOSURES OF FINANCIAL RELATIONSHIPS
In accordance with the ACCME Standards for Commercial Support, the AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with a commercial interest. The following individuals contributed to this activity’s content.
Faculty & Planners
Dennis Dlugos, M.D, Childrens Hospital of Philadelphia, Philadelphia, PA
Dr. Dlugos has indicated he has no financial relationships to disclose relevant to this activity.
Tracy Glauser, M.D., Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Disclosure: Dr. Glauser has disclosed the following relevant financial relationships: Royalties, Intellectual Property Rights, Ownership interest from AssureX Health, Consulting Fee from Supernus, Scientific Advisory Board member for AssureX Helath, Claritas Genomics, and Expert witness for Eisai.
AES Staff
AES Staff involved in this activity have indicated they have no financial relationships to disclose relevant to this activity.
CME Reviewer
Dennis Dlugos, M.D, Childrens Hospital of Philadelphia, Philadelphia, PA
Dr. Dlugos has indicated he has no financial relationships to disclose relevant to this activity.
Accreditation
The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The American Epilepsy Society designates this live activity for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Certificates
To receive your CME certificate for completing this activity, complete the evaluation survey at the conclusion of the live activity.
Resolution of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support of CME, the AES implemented the mechanisms of prospective peer review of this CME activity, to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.
Unapproved Use Disclosure
The American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.
Disclaimer
This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.